Evolent Health Inc
NYSE:EVH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (29.2), the stock would be worth $2.92 (1% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 29.6 | $2.95 |
0%
|
| 3-Year Average | 29.2 | $2.92 |
-1%
|
| 5-Year Average | 29.2 | $2.92 |
-1%
|
| Industry Average | 18.7 | $1.86 |
-37%
|
| Country Average | 16.7 | $1.67 |
-44%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Evolent Health Inc
NYSE:EVH
|
329.3m USD | 29.6 | -0.6 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 18.9 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
25.6B USD | 13.6 | 28.5 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.8B AUD | 111.5 | 61.7 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 13.6 | 20.5 | |
| SE |
|
Sectra AB
STO:SECT B
|
51.8B SEK | 63.2 | 96.4 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.8B USD | 19.5 | 41.5 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.3B USD | 11.4 | 18 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19.3B CNY | 38.2 | -62.7 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 61.3 | -328 | |
| US |
H
|
Heartflow Inc
NASDAQ:HTFL
|
2.7B USD | 0 | 0 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Evolent Health Inc
Glance View
Evolent Health Inc. emerged in 2011 from a collaboration between The Advisory Board Company and the University of Pittsburgh Medical Center, with a mission to reshape healthcare delivery in the United States. As the healthcare landscape shifted towards value-based care models, where providers are compensated for keeping patients healthy rather than on the volume of services delivered, Evolent positioned itself as a pivotal partner for healthcare systems aiming to transition smoothly into this new paradigm. The company's core offerings revolve around its technology-driven platform, which integrates data analytics, care management, and clinical expertise to enable healthcare providers and payers to deliver more efficient and patient-centric care. By providing these services, Evolent helps its clients reduce costs and improve patient outcomes, thus thriving in a rapidly evolving industry. From a business perspective, Evolent Health generates revenue primarily through two streams: provider services and performance-based contracts. For its provider services, Evolent signs agreements with healthcare providers, offering them proprietary technology and consulting services, all designed to enhance their operational efficiency and clinical capabilities. The performance-based contracts, which are fundamental in a value-based care environment, allow Evolent to share in the financial benefits realized by its clients from improved patient care and cost savings. This model not only aligns Evolent's success with that of its clients but also positions the company at the heart of the healthcare value chain, asserting its influence through partnerships that are financially symbiotic.